Ashwani Verma
Stock Analyst at UBS
(3.08)
# 1,093
Out of 4,479 analysts
41
Total ratings
43.33%
Success rate
2.34%
Average return
Main Sectors:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITCI Intra-Cellular Therapies | Downgrades: Neutral | $85 → $83 | $68.86 | +20.53% | 4 | Jun 25, 2024 | |
| RPRX Royalty Pharma | Downgrades: Neutral | $28 | $25.89 | +8.17% | 3 | Jun 3, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $174 → $193 | $138.31 | +39.54% | 4 | May 28, 2024 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Buy | $59 → $60 | $34.39 | +74.47% | 2 | Apr 23, 2024 | |
| LEGN Legend Biotech | Maintains: Buy | $76 → $81 | $44.74 | +81.05% | 2 | Mar 18, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Neutral | $135 → $131 | $105.29 | +24.42% | 4 | Mar 1, 2024 | |
| ALKS Alkermes | Downgrades: Sell | $25 | $24.23 | +3.18% | 2 | Feb 20, 2024 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $111 | $80.61 | +37.70% | 1 | Feb 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Initiates: Buy | $21 | $13.95 | +50.54% | 1 | Feb 6, 2024 | |
| CYTK Cytokinetics | Downgrades: Neutral | $61 → $92 | $54.60 | +68.50% | 4 | Jan 24, 2024 | |
| TEVA Teva Pharmaceutical | Upgrades: Buy | $11 → $13 | $16.52 | -21.28% | 4 | Nov 27, 2023 | |
| ACLX Arcellx | Initiates: Buy | $52 | $53.17 | -2.20% | 1 | Oct 17, 2023 | |
| ACAD ACADIA Pharmaceuticals | Initiates: Buy | $33 | $15.95 | +106.90% | 1 | Oct 17, 2023 | |
| COHR Coherent | Maintains: Buy | $11 → $7 | $73.69 | -90.50% | 1 | Aug 7, 2023 | |
| UTHR United Therapeutics | Maintains: Buy | $330 → $310 | $319.54 | -2.99% | 2 | Apr 10, 2023 | |
| CHRS Coherus BioSciences | Upgrades: Buy | $11 | $1.40 | +688.53% | 2 | Mar 28, 2023 | |
| VTRS Viatris | Upgrades: Neutral | $9 → $12 | $10.40 | +15.44% | 2 | Nov 10, 2022 | |
| RANI Rani Therapeutics Holdings | Initiates: Buy | $15 | $3.89 | +286.10% | 1 | Oct 11, 2022 |
Intra-Cellular Therapies
Jun 25, 2024
Downgrades: Neutral
Price Target: $85 → $83
Current: $68.86
Upside: +20.53%
Royalty Pharma
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $25.89
Upside: +8.17%
Neurocrine Biosciences
May 28, 2024
Maintains: Buy
Price Target: $174 → $193
Current: $138.31
Upside: +39.54%
Biohaven Pharmaceutical Holding Company
Apr 23, 2024
Maintains: Buy
Price Target: $59 → $60
Current: $34.39
Upside: +74.47%
Legend Biotech
Mar 18, 2024
Maintains: Buy
Price Target: $76 → $81
Current: $44.74
Upside: +81.05%
Jazz Pharmaceuticals
Mar 1, 2024
Maintains: Neutral
Price Target: $135 → $131
Current: $105.29
Upside: +24.42%
Alkermes
Feb 20, 2024
Downgrades: Sell
Price Target: $25
Current: $24.23
Upside: +3.18%
Axsome Therapeutics
Feb 6, 2024
Initiates: Buy
Price Target: $111
Current: $80.61
Upside: +37.70%
Avadel Pharmaceuticals
Feb 6, 2024
Initiates: Buy
Price Target: $21
Current: $13.95
Upside: +50.54%
Cytokinetics
Jan 24, 2024
Downgrades: Neutral
Price Target: $61 → $92
Current: $54.60
Upside: +68.50%
Teva Pharmaceutical
Nov 27, 2023
Upgrades: Buy
Price Target: $11 → $13
Current: $16.52
Upside: -21.28%
Arcellx
Oct 17, 2023
Initiates: Buy
Price Target: $52
Current: $53.17
Upside: -2.20%
ACADIA Pharmaceuticals
Oct 17, 2023
Initiates: Buy
Price Target: $33
Current: $15.95
Upside: +106.90%
Coherent
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $73.69
Upside: -90.50%
United Therapeutics
Apr 10, 2023
Maintains: Buy
Price Target: $330 → $310
Current: $319.54
Upside: -2.99%
Coherus BioSciences
Mar 28, 2023
Upgrades: Buy
Price Target: $11
Current: $1.40
Upside: +688.53%
Viatris
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $10.40
Upside: +15.44%
Rani Therapeutics Holdings
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $3.89
Upside: +286.10%